Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment

Vaccine. 2010 Mar 2;28(10):2201-2206. doi: 10.1016/j.vaccine.2009.12.056. Epub 2010 Jan 5.

Abstract

Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Dendritic Cells / immunology*
  • Ethnicity
  • Gene Frequency
  • Genotype
  • HIV Infections / therapy*
  • Humans
  • Immunity, Innate / genetics*
  • Immunotherapy / methods*
  • Mannose-Binding Lectin / genetics
  • Nitric Oxide Synthase Type I / genetics
  • Polymorphism, Single Nucleotide*

Substances

  • AIDS Vaccines
  • MBL2 protein, human
  • Mannose-Binding Lectin
  • NOS1 protein, human
  • Nitric Oxide Synthase Type I